Analyzing Prostate Cancer Using the CTC-Chip – Insights into the Prognosis of Recurrent Prostate Cancer

Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]

Calling Dendreon’s Call Center & Being Told To Call Back

I have heard back that a number of people have contacted the call center at Dendreon (877-336-3736) and been told to call back at a later date for specific information about getting treatment. I have spoken with Dendreon and they have explained that they are working with the various infusion centers on mapping out specific [...]

THE FDA HAS APPROVED PROVENGE

Provenge has finally received the long awaited approval from the FDA!!! We all celebrate and look forward to benefiting from its potential to extend our life. Provenge is the first immunologic therapy ever approved in the United States to treat cancer. (In Russia, Antigenics has received approval for an immunological treatment for kidney cancer). The [...]

From The AACR Meeting – Identifying New Drugs That Block Prostate Tumor Growth

Researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth. Their research was presented at the recent Annual Meeting of the American Association for Cancer Research (AACR) which I had the good fortune to attend. As we know the common treatment for localized [...]

Go to Top